Article ; Online: Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials.
2024 Volume 45, Issue 4, Page(s) 341–348
Abstract: Objectives: To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.: Methods: PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized ... ...
Abstract | Objectives: To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients. Methods: PubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023. Results: A total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially. Conclusion: Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding. |
---|---|
MeSH term(s) | Humans ; Rivaroxaban/therapeutic use ; Rivaroxaban/adverse effects ; Randomized Controlled Trials as Topic ; Anticoagulants/therapeutic use ; Anticoagulants/adverse effects ; COVID-19/complications ; COVID-19 Drug Treatment ; Hemorrhage/chemically induced ; Heparin, Low-Molecular-Weight/therapeutic use ; Heparin, Low-Molecular-Weight/adverse effects ; Factor Xa Inhibitors/therapeutic use ; Factor Xa Inhibitors/adverse effects ; Thrombosis/prevention & control ; Thrombosis/etiology ; Treatment Outcome ; Heparin/therapeutic use ; Heparin/adverse effects ; SARS-CoV-2 |
Chemical Substances | Rivaroxaban (9NDF7JZ4M3) ; Anticoagulants ; Heparin, Low-Molecular-Weight ; Factor Xa Inhibitors ; Heparin (9005-49-6) |
Language | English |
Publishing date | 2024-04-23 |
Publishing country | Saudi Arabia |
Document type | Journal Article ; Meta-Analysis |
ZDB-ID | 392302-2 |
ISSN | 1658-3175 ; 0379-5284 |
ISSN (online) | 1658-3175 |
ISSN | 0379-5284 |
DOI | 10.15537/smj.2024.45.4.20230728 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 2330: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MB 6: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.